Drug intelligence / Profile preview

GNX80

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

GNX80 is an orally administered small molecule drug. Its precise mechanism of action is currently unknown. GNX80 has been investigated in a Phase 4 randomized clinical trial for the treatment of intermittent claudication, a condition characterized by pain caused by too little blood flow during exercise, typically due to peripheral artery disease[1][2]. There are no FDA designations or approvals associated with this compound at this time[1].

Beyond the preview

Go deeper on GNX80.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNX80.

Explore the full profile